OS Therapies Revenue and Competitors
Estimated Revenue & Valuation
- OS Therapies's estimated annual revenue is currently $387.5k per year.
- OS Therapies's estimated revenue per employee is $77,500
- OS Therapies's total funding is $7M.
Employee Data
- OS Therapies has 5 Employees.
- OS Therapies grew their employee count by -17% last year.
OS Therapies's People
| Name | Title | Email/Phone |
|---|
OS Therapies Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is OS Therapies?
OS
keywords:N/A
$7M
Total Funding
5
Number of Employees
$387.5k
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OS Therapies News
2022-04-19 - TG Therapeutics: Can The Company Successfully Turn Around?
Again, OS is a secondary endpoint that is not a requisite but it would support approval. This is where the plot thickens. Specifically, the FDA...
2022-04-17 - Ublituximab/Umbralisib Applications Voluntary Withdrawn for ...
TG Therapeutics made the decision to voluntarily pull the biologics ... which highlighted a growing imbalance in overall survival (OS).
2022-04-06 - Form of HLA gene associated with shorter OS after immune ...
Although immune checkpoint inhibition is used to treat many cancers, for most cancer types fewer than 50% of patients respond to therapy.
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 5 | -17% | $76.7M |
#2 | $0.7M | 5 | N/A | N/A |
#3 | $0.3M | 5 | N/A | N/A |
#4 | $0.5M | 5 | N/A | N/A |
#5 | $0.5M | 5 | N/A | N/A |